Dr. Don Eslin, MD
Claim this profileSaint Joseph's Hospital/Children's Hospital-Tampa
Expert in Cancer
Expert in Lymphoma
58 reported clinical trials
114 drugs studied
About Don Eslin, MD
Education:
- Obtained MD from the University of South Florida Morsani College of Medicine in 2015.
- Completed Residency in Pediatrics at St. Joseph's Children's Hospital, Tampa, FL (2015-2018).
- Undertook Fellowship in Pediatric Cardiology at Johns Hopkins All Children's Hospital, St. Petersburg, FL (2018-2021).
Experience:
- Currently practices as a pediatric cardiologist at St. Joseph's Children's Hospital/Children's Hospital-Tampa.
Area of expertise
1Cancer
Global LeaderStage I
Stage IV
Stage II
2Lymphoma
Global LeaderStage IV
Stage I
Stage II
Affiliated Hospitals
Clinical Trials Don Eslin, MD is currently running
Genetic Testing-Directed Therapy
for Pediatric Cancer
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.
Recruiting1 award Phase 214 criteria
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
More about Don Eslin, MD
Clinical Trial Related7 years of experience running clinical trials · Led 58 trials as a Principal Investigator · 27 Active Clinical TrialsTreatments Don Eslin, MD has experience with
- Cyclophosphamide
- Radiation Therapy
- Etoposide
- Nivolumab
- Vincristine Sulfate
- Doxorubicin Hydrochloride
Breakdown of trials Don Eslin, MD has run
Cancer
Lymphoma
Neuroblastoma
Brain Tumor
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Don Eslin, MD specialize in?
Don Eslin, MD focuses on Cancer and Lymphoma. In particular, much of their work with Cancer has involved Stage I patients, or patients who are Stage IV.
Is Don Eslin, MD currently recruiting for clinical trials?
Yes, Don Eslin, MD is currently recruiting for 20 clinical trials in Tampa Florida. If you're interested in participating, you should apply.
Are there any treatments that Don Eslin, MD has studied deeply?
Yes, Don Eslin, MD has studied treatments such as Cyclophosphamide, Radiation Therapy, Etoposide.
What is the best way to schedule an appointment with Don Eslin, MD?
Apply for one of the trials that Don Eslin, MD is conducting.
What is the office address of Don Eslin, MD?
The office of Don Eslin, MD is located at: Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa, Florida 33607 United States. This is the address for their practice at the Saint Joseph's Hospital/Children's Hospital-Tampa.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.